Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. - Wick,M.C.; Ernestam,S.; Linblad,S. (Scand J Rheumatol, 2005)